GlassScriptPhysician profile
James Foshee
NPI 1689037152
$1,429.35
in general payments reported to CMS, 2019-2025
21 companies · $231 in 2025
The $231 reported for 2025 was less than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $46.64 · 2021: $177 · 2022: $426 · 2023: $414 · 2024: $134 · 2025: $231.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $779.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $778.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $241.15 | 2021-2025 | |
| Janssen Biotech, INC. | $184.21 | 2022-2024 | Tremfya, Simponi, Simponi Aria |
| Mimedx Group, INC. | $157.94 | 2024-2025 | |
| Amgen INC. | $155.02 | 2021-2024 | Otezla, Enbrel |
| Sun Pharmaceutical Industries INC. | $135.47 | 2023-2024 | Odomzo, Blu-U |
| Lilly USA, LLC | $98.05 | 2019-2023 | Taltz, Olumiant |
| Leo Pharma INC. | $67.08 | 2021-2022 | |
| Incyte Corporation | $45.92 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $45.76 | 2023 | Sotyktu |
| Genzyme Corporation | $45.62 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $43.86 | 2021-2023 | Libtayo |
| Strata Skin Sciences, INC. | $33.22 | 2025 | Xtrac |
| Genentech USA, INC. | $24.26 | 2021 | |
| Organogenesis INC. | $23.42 | 2025 | Puraply Wound Matrix |
| Surgenex LLC | $23.32 | 2025 | Ardeograft, Surgraft, Surmatrix |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $21.29 | 2023 | |
| Almirall LLC | $20.79 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $18.81 | 2023 | Jublia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.87 | 2023 | Cyltezo |
| Helsinn Therapeutics (U.S.), INC. | $15.03 | 2021 | |
| Mayne Pharma Commercial LLC | $13.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Foshee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.